Published in Ann Neurol on September 01, 1999
Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA (2011) 5.21
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature (2009) 4.43
Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nat Struct Mol Biol (2010) 3.75
Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 3.61
Biomarkers of Alzheimer disease in plasma. NeuroRx (2004) 2.02
Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol (2014) 1.86
Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci U S A (2008) 1.84
Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology (2008) 1.71
Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol (2009) 1.47
Fluid biomarkers in Alzheimer's disease - current concepts. Mol Neurodegener (2013) 1.44
A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol (2009) 1.44
Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol (2011) 1.40
Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. Arch Neurol (2012) 1.37
Biomarkers of Alzheimer's disease. Neurobiol Dis (2008) 1.37
Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol (2007) 1.36
Fine mapping of the alpha-T catenin gene to a quantitative trait locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Hum Mol Genet (2003) 1.32
The vascular contribution to Alzheimer's disease. Clin Sci (Lond) (2010) 1.21
Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid Redox Signal (2013) 1.20
Alzheimer disease therapy: can the amyloid cascade be halted? J Clin Invest (2003) 1.19
Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome. Arch Neurol (2007) 1.19
Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer's disease. J Alzheimers Dis (2010) 1.18
Amyloid-associated depression: a prodromal depression of Alzheimer disease? Arch Gen Psychiatry (2008) 1.18
Plasma ß-amyloid and cognitive decline. Arch Neurol (2010) 1.13
Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism. Am J Pathol (2000) 1.09
Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker. Alzheimers Res Ther (2013) 1.06
Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol (2008) 1.04
A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study. Mol Psychiatry (2013) 1.03
Marked increase of beta-amyloid(1-42) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury. J Neurol (2004) 1.01
Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer's disease. Neuromolecular Med (2008) 0.98
Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults. Am J Geriatr Psychiatry (2009) 0.97
Change in plasma Aß peptides and onset of dementia in adults with Down syndrome. Neurology (2010) 0.96
Comparison of conventional ELISA with electrochemiluminescence technology for detection of amyloid-β in plasma. J Alzheimers Dis (2010) 0.94
Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome. J Alzheimers Dis (2011) 0.94
Nutrient intake and plasma β-amyloid. Neurology (2012) 0.93
The role of inflammatory processes in Alzheimer's disease. Inflammopharmacology (2012) 0.92
Zn(++) binding disrupts the Asp(23)-Lys(28) salt bridge without altering the hairpin-shaped cross-β Structure of Aβ(42) amyloid aggregates. Biophys J (2011) 0.91
Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's disease. J Alzheimers Dis (2011) 0.91
Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. J Neural Transm (Vienna) (2012) 0.90
Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants. Neurobiol Aging (2011) 0.90
Depression and plasma amyloid beta peptides in the elderly with and without the apolipoprotein E4 allele. Alzheimer Dis Assoc Disord (2009) 0.90
Unfolded p53 in the pathogenesis of Alzheimer's disease: is HIPK2 the link? Aging (Albany NY) (2010) 0.89
The Role of Clinical Proteomics, Lipidomics, and Genomics in the Diagnosis of Alzheimer's Disease. Proteomes (2016) 0.85
Increased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients. PLoS One (2013) 0.82
Severe Cognitive Dysfunction and Occupational Extremely Low Frequency Magnetic Field Exposure among Elderly Mexican Americans. Br J Med Med Res (2014) 0.82
Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome. Int J Geriatr Psychiatry (2010) 0.81
Solid-state NMR as a probe of amyloid structure. Protein Pept Lett (2006) 0.81
Candidate genes for Alzheimer's disease are associated with individual differences in plasma levels of beta amyloid peptides in adults with Down syndrome. Neurobiol Aging (2015) 0.80
Angiotensin converting enzyme inhibitors and Alzheimer disease in the presence of the apolipoprotein E4 allele. Am J Geriatr Psychiatry (2013) 0.79
Genetic diagnosis and prognosis of Alzheimer's disease: challenges and opportunities. Expert Rev Mol Diagn (2015) 0.79
Circulating biomarkers that predict incident dementia. Alzheimers Res Ther (2014) 0.77
Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. Alzheimers Dement (2014) 0.77
A systematic review and meta-analysis of plasma amyloid 1-42 and tau as biomarkers for Alzheimer's disease. SAGE Open Med (2015) 0.77
Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial. J Alzheimers Dis (2016) 0.75
Multiplex biomarkers in blood. Alzheimers Res Ther (2013) 0.75
Ion Channel Formation by Amyloid-β42 Oligomers but not Amyloid-β40 in Cellular Membranes. J Biol Chem (2016) 0.75
Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin (2017) 0.75
Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A (1986) 10.13
Influence of education and occupation on the incidence of Alzheimer's disease. JAMA (1994) 8.43
The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA (1998) 7.81
Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes (1999) 7.14
Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet (1996) 7.10
Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol (1987) 7.05
Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem (1986) 6.91
Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology (2001) 5.98
Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry (1976) 5.43
Abnormal fibrils from scrapie-infected brain. Acta Neuropathol (1981) 5.35
Influence of leisure activity on the incidence of Alzheimer's disease. Neurology (2001) 4.49
Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology (2005) 4.04
Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology (2007) 3.97
Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides. Proc Natl Acad Sci U S A (1987) 3.97
Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology (1995) 3.91
Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol (1985) 3.83
Repeated cocaine augments excitatory amino acid transmission in the nucleus accumbens only in rats having developed behavioral sensitization. J Neurosci (1996) 3.66
Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up. Am J Psychiatry (2000) 3.54
Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol (2001) 3.43
The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience (2000) 3.40
Neuropsychological detection and characterization of preclinical Alzheimer's disease. Neurology (1995) 3.37
Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med (1998) 3.23
Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol (2000) 3.18
Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA (1997) 3.17
Rate of memory decline in AD is related to education and occupation: cognitive reserve? Neurology (1999) 3.12
Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res (1989) 3.10
The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am J Epidemiol (1995) 3.00
Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging (2005) 3.00
Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Gen Psychiatry (1996) 2.99
Alzheimer paired helical filaments: bulk isolation, solubility, and protein composition. Acta Neuropathol (1984) 2.97
Depression, intellectual impairment, and Parkinson disease. Neurology (1981) 2.96
Rates of dementia in three ethnoracial groups. Int J Geriatr Psychiatry (1999) 2.92
Isolation of a lipid A bound polypeptide responsible for "LPS-initiated" mitogenesis of C3H/HeJ spleen cells. J Exp Med (1976) 2.88
Functional deficits in patients with mild cognitive impairment: prediction of AD. Neurology (2002) 2.79
Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology (1999) 2.74
Alzheimer paired helical filaments: immunochemical identification of polypeptides. Acta Neuropathol (1984) 2.70
Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease. Neurobiol Aging (1997) 2.68
Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol (2000) 2.66
Alzheimer neurofibrillary tangles: monoclonal antibodies to inherent antigen(s). Acta Neuropathol (1984) 2.58
Alzheimer neurofibrillary tangles in diseases other than senile and presenile dementia. Ann Neurol (1979) 2.50
The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease. Ann Neurol (1993) 2.48
Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology (2003) 2.44
Cognitive impairment after stroke: frequency, patterns, and relationship to functional abilities. J Neurol Neurosurg Psychiatry (1994) 2.40
Infection-specific particle from the unconventional slow virus diseases. Science (1984) 2.34
Stimulation of a T-independent primary anti-hapten response in vitro by TNP-lipopolysaccharide (TNP-LPS). J Immunol (1975) 2.30
Education and rates of cognitive decline in incident Alzheimer's disease. J Neurol Neurosurg Psychiatry (2006) 2.29
Cognitive test performance among nondemented elderly African Americans and whites. Neurology (1998) 2.28
Ultrastructural morphology of amyloid fibrils from neuritic and amyloid plaques. Acta Neuropathol (1983) 2.23
Premorbid weight, body mass, and varsity athletics in ALS. Neurology (2002) 2.23
Evidence that Alzheimer neurofibrillary tangles originate from neurotubules. Lancet (1979) 2.22
Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology (2004) 2.18
Therapeutic hypothermia in comatose patients after out-of-hospital cardiac arrest. Anaesthesia (2008) 2.17
Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci (2001) 2.15
The influence of smoking on the risk of Alzheimer's disease. Neurology (1999) 2.14
Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease. Ann Neurol (1999) 2.13
Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci (2007) 2.11
Scrapie-associated fibrils in Creutzfeldt-Jakob disease. Nature (1984) 2.11
Clinical and molecular delineation of the 17q21.31 microdeletion syndrome. J Med Genet (2008) 2.09
Attachment and adolescent psychosocial functioning. Child Dev (1998) 2.07
The association of incident dementia with mortality in PD. Neurology (2002) 2.07
Immunological comparison of scrapie-associated fibrils isolated from animals infected with four different scrapie strains. J Virol (1986) 1.95
APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology (2008) 1.91
Effect of literacy on neuropsychological test performance in nondemented, education-matched elders. J Int Neuropsychol Soc (1999) 1.91
Defective brain microtubule assembly in Alzheimer's disease. Lancet (1986) 1.89
Nitric oxide and carbon monoxide produce activity-dependent long-term synaptic enhancement in hippocampus. Science (1993) 1.89
Malignancy, mortality, and medicosurgical management of Clostridium septicum infection. Surgery (1995) 1.87
MRI of entorhinal cortex in mild Alzheimer's disease. Lancet (1999) 1.86
Ultrastructure of paired helical filaments of Alzheimer's neurofibrillary tangle. J Neuropathol Exp Neurol (1984) 1.86
A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry (1998) 1.85
Is "subcortical dementia" a recognizable clinical entity? Ann Neurol (1983) 1.85
Apolipoprotein E and Alzheimer's disease: ethnic variation in genotypic risks. Ann Neurol (1995) 1.85
Neuropsychological characteristics of preclinical dementia in Parkinson's disease. Neurology (1995) 1.84
A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. JAMA (2001) 1.82
Spatio-temporal analysis of molecular delivery through the blood-brain barrier using focused ultrasound. Phys Med Biol (2007) 1.81
Heterogeneity in dementia of the Alzheimer type: evidence of subgroups. Neurology (1985) 1.81
Adult fragile X syndrome. Clinico-neuropathologic findings. Acta Neuropathol (1985) 1.80